A Pan-Canadian, Investigator Initiated Clinical Trial With Focal IRE Directed to Intermediate-Risk Prostate Cancer

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 16, 2024

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2033

Conditions
Prostate Cancer
Interventions
DEVICE

Irreversible Electroporation (NanoKnife)

Irreversible Electroporation (IRE) using NanoKnife technology uses high voltage current pulses via probes placed around the prostate tumour via the perineum. The electricity damages the cell membranes rendering the cells dead. Hypothesized benefits of IRE over other focal therapy options include the ability to treat large or small lesions. Also, because the technology spares vessels, it can be used to treat prostate areas adjacent to sensitive structures (ie prostate apex near the sphincter and lateral peripheral zone near the neurovascular bundle). Finally, treatments take approximately 1-1.5 hours, thus the technology could be used to treat several patients per day.

Trial Locations (1)

M5G 2C4

RECRUITING

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER